CN Bio has launched the PhysioMimix® DILI Assay Kit: Human 24, a first-of-its-kind Organ-on-a-Chip (OOC) solution designed to support pharmaceutical and biotech laboratories in assessing drug-induced liver injury (DILI) with greater accuracy. By leveraging primary human liver tissue and Kupffer cells, the kit provides more predictive toxicology data, de-risking drug development pipelines.
Overcoming limitations in preclinical drug testing
Traditional in vitro and in vivo models often lack clinical relevance, leading to unexpected hepatotoxicity in clinical trials. CN Bio’s liver microphysiological system (MPS) mimics the human liver environment, capturing key metabolic and immune responses that traditional assays overlook.
How this kit benefits lab managers
- Plug-and-play format simplifies implementation, reducing time to adoption
- Eliminates need for in-house MPS model development, lowering operational barriers
- Improves predictive accuracy, reducing costly late-stage drug failures
- Scales for multiple drug candidates, streamlining preclinical workflows
- Generates mechanistic insights into hepatotoxicity, supporting regulatory submissions
Bringing advanced toxicology testing in-house
Previously only available as a contract research service (CRS), the PhysioMimix® DILI Assay Kit empowers labs to internalize high-fidelity hepatotoxicity testing, reducing reliance on animal models and outsourced studies. This advancement enhances decision-making in early drug discovery, ensuring only the safest candidates progress to clinical trials.
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release, visit: "CN Bio launches PhysioMimix® DILI assay kit: Human 24"
